Browse News
Filter News
Found 53 articles
-
Arsenal Biosciences Announces Presentation of Four Abstracts at AACR Annual Meeting Highlighting New CAR T-Focused Research
4/5/2024
Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced the presentation of four abstracts at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA., May 5-10, 2024.
-
Arsenal Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/2/2024
Arsenal Biosciences, Inc. (ArsenalBio) today announced that Ken Drazan, MD, the company’s Chairman and Chief Executive Officer, will present a corporate update at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 9:30 a.m. PT.
-
Biogen Appoints Jane Grogan as Head of Research
9/6/2023
Biogen Inc. (Nasdaq: BIIB) announced the appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research effective 2 October 2023.
-
Simcha Therapeutics Announces its Scientific Advisory Board, Comprised of Renowned Experts in Immunology and Oncology
8/22/2023
Simcha Therapeutics today announced the formation of a scientific advisory board that will support the company’s efforts to realize the potential of IL-18-focused therapeutic approaches.
-
Azitra Adds Biotech Leaders Barbara Ryan and John Schroer to Its Board of Directors
7/19/2023
Azitra, Inc. announced the addition of two members to its board of directors, Barbara Ryan and John Schroer.
-
Arsenal Bio Announces Presentations Highlighting Preclinical Data on AB-1015 and AB-2100 at ASGCT Annual Meeting
5/16/2023
Arsenal Biosciences, Inc. today announced that it will present preclinical data on its integrated circuit T cell therapies, AB-1015 and AB-2100, in an oral abstract session and three posters at the American Society of Gene and Cell Therapy (ASGCT) annual meeting in Los Angeles, Calif., May 16-20, 2023.
-
ArsenalBio Announces Presentation of Six Abstracts at AACR Annual Meeting Highlighting Programmable Cell Therapy Progress
4/14/2023
Company to share preclinical data on the use of integrated circuit T cells for the development of cell therapies for the treatment of kidney and other solid tumor cancers.
-
Thermo Fisher Scientific and Arsenal Biosciences Collaborate to Support Clinical Manufacturing of Autologous T-Cell Therapies
3/29/2023
Thermo Fisher Scientific today announced an update to our strategic collaboration to further the development of manufacturing processes for new cancer treatments.
-
ArsenalBio Announces First Patient Dosed in Phase 1 Clinical Trial of AB-1015 in Development as a Treatment for Ovarian Cancer
1/5/2023
Arsenal Biosciences, Inc. today announced that the first patient has been dosed with AB-1015 in a Phase 1, first-in-human clinical trial for patients with ovarian cancer that is resistant to platinum-based regimens.
-
Belharra Launches with $130M From Versant, Genentech to Advance Chemoproteomics Platform (Updated)
1/4/2023
Backed by Versant and Genentech, Belharra Therapeutics launched Wednesday with $130 million in total financing to advance its novel chemoproteomics platform. -
Pixelgen Technologies Launches to Advance Single-Cell Spatial Proteomics
12/7/2022
Pixelgen Technologies emerged from stealth today with a mission to bring a new dimension to single-cell spatial proteomics.
-
BioSpace's 2023 “Best Places to Work,” highlights innovative companies with a positive workplace culture, flexibility and strong leadership.
-
Meliora Therapeutics Raises $11M Seed Financing to Develop First Mechanism Of Action Atlas in Oncology
9/29/2022
Meliora Therapeutics announced today the close of an $11M seed financing round led by HOF Capital and ZhenFund, with participation from Obvious Ventures, Village Global, BrightEdge.
-
Genentech and privately-held Arsenal Biosciences forged a multi-year collaboration to identify critical success circuits in T cell-based therapies for solid tumors.
-
Gladstone Institutes Joins the Parker Institute for Cancer Immunotherapy Network
9/28/2022
Gladstone Institutes has partnered with the Parker Institute for Cancer Immunotherapy, the leading network of immuno-oncology expertise in the world, to establish a new research center focused on using genomics and CRISPR technology to program the human immune system to treat cancer.
-
Arsenal Biosciences Announces Joint Discovery Collaboration with Genentech to Identify Features of Successful T-Cell Therapies for Oncology
9/27/2022
Arsenal Biosciences, Inc. today announced a multi-year collaboration with Genentech, a member of the Roche Group.
-
Arcutis scoops up Ducentis and its lead asset DS-234, UC San Diego receives $150M earmarked for stem cell, regenerative medicine research and Arsenal and ILiAD reel in new funds.
-
Arsenal Biosciences Closes $220 Million Series B Financing to Advance Programmable Cell Therapy Programs into Clinical Development
9/6/2022
Arsenal Biosciences, Inc. (ArsenalBio), a privately held programmable cell therapy company engineering advanced CAR T therapies for solid tumors, today announced the close of a $220 million Series B financing round.
-
Orange Grove Bio Provides Corporate Update Highlighting Key Leadership Appointments and Establishment of New Academic Collaboration
6/23/2022
John C. Byrd, M.D., Renowned Cancer Clinician and Researcher, Named Chair of Scientific Advisory Board.
-
Arsenal Biosciences to Present at the 2022 Jefferies Healthcare Conference
6/2/2022
Arsenal Biosciences, Inc., a privately held programmable cell therapy company engineering advanced CAR T therapies for solid tumors, today announced that the company’s Chief Executive Officer, Ken Drazan, MD, will present in person at the 2022 Jefferies Healthcare Conference on Thursday, June 9 at 4:00 p.m. Eastern time.